Q-omics provides the consensus-scored RNY3P2 profile across patient tissues and cancer cell-line models. RNY3P2 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RNY3P2 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, RNY3P2 RNA expression shows 8,538 significant gene co-expression associations, with the highest sampling consensus in BRCA. Together, these results highlight HNSC, KIRC, and BRCA as cancer lineages where RNY3P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNY3P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNY3P2 survival associations across molecular data types. RNY3P2 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNY3P2 RNA expression–survival associations across cancer types. High RNY3P2 expression shows unfavorable associations in HNSC, READ, KIRP, TGCT, LUAD and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RNY3P2 RNA expression.
This table summarizes RNY3P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNY3P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNY3P2 shows lower tumor expression in KIRC and higher tumor expression in STAD. The KIRC box plot shows higher RNY3P2 RNA expression in normal versus tumor tissue (log2 FC = −0.046, t-test p = .022).
This table shows molecular features associated with RNY3P2 in patient tissues and cancer cell lines. In patient samples, RNY3P2 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
